Literature DB >> 15109585

Treatment of depression in Parkinson's disease.

Karen A Sawabini1, Ray L Watts.   

Abstract

Depression is an important and common nonmotor feature of Parkinson's disease (PD) that is associated with significant disability and a negative impact on quality of life. The physician should remain vigilant for symptoms of depression as they may be mistaken for the progression of Parkinson's disease itself. Transient dysphoria that occurs during 'off' periods in fluctuating PD patients must be distinguished from true depression. Antidepressant therapy should be instituted if depression is interfering with the patient's daily function. The use of serotonin reuptake inhibitors and tricyclic antidepressants in the treatment of depression in PD is widespread in clinical practice. Dopamine agonists may be effective in the treatment of milder depression as well. Individual or family counseling may be helpful. In patients with severe depression who are refractory to antidepressant medications, a series of electroconvulsive treatments can be lifesaving. Nonconventional therapies such as transcranial magnetic stimulation are being investigated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15109585     DOI: 10.1016/j.parkreldis.2004.02.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  6 in total

1.  The effects of dopaminergic/serotonergic reuptake inhibition on maternal behavior, maternal aggression, and oxytocin in the rat.

Authors:  J M Johns; P W Joyner; M S McMurray; D L Elliott; V E Hofler; C L Middleton; K Knupp; K W Greenhill; L M Lomas; C H Walker
Journal:  Pharmacol Biochem Behav       Date:  2005-08       Impact factor: 3.533

2.  Monoamine transporter availability in Parkinson's disease patients with or without depression.

Authors:  Swen Hesse; Philipp M Meyer; Karl Strecker; Henryk Barthel; Florian Wegner; Christian Oehlwein; Ioannis Ugo Isaias; Johannes Schwarz; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-27       Impact factor: 9.236

3.  Sertraline in the treatment of depressive disorders in patients with Parkinson's disease.

Authors:  Silvia Marino; Edoardo Sessa; Giuseppe Di Lorenzo; Giuseppina Digangi; Antonella Alagna; Placido Bramanti; Paolo Di Bella
Journal:  Neurol Sci       Date:  2008-11-11       Impact factor: 3.307

4.  Adult neural stem cells: The promise of the future.

Authors:  Philippe Taupin
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

5.  Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinson's Disease.

Authors:  Camilla Elefante; Giulio Emilio Brancati; Silvia Bacciardi; Sonia Mazzucchi; Eleonora Del Prete; Giovanni Palermo; Daniela Frosini; Ubaldo Bonuccelli; Roberto Ceravolo; Lorenzo Lattanzi; Icro Maremmani; Giulio Perugi
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

6.  Adult neural stem cells: redefining the physio- and pathology of the CNS.

Authors:  Philippe Taupin
Journal:  Int J Biomed Sci       Date:  2008-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.